Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29803343 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL8892308 | 0.92 | KMT2A (0.57) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL8251640 | 0.91 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29477078 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL119400 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29352152 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL2551441 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1486209 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1486191 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL31610887 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| EP-4037702-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114746103-A | Rapafucin derivative compounds and methods of use thereof | 约翰霍普金斯大学 | 2022-07-12 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | KMT2A 4739/4885CASP3 3018/4885MDM4 3276/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | KMT2A 4797/4885CASP3 4349/4885MDM4 4656/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | KMT2A 4771/4885CASP3 3219/4885MDM4 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.